Table 2. Laboratory parameters and exacerbations in 166 adult (A) and in 106 pediatric (B) pwCF at baseline and after 1 year of ETI therapy and in age/sex-matched healthy controls.

From: Blood platelet reduction after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis may depend on systemic inflammation reduction

 

HCs

CF

 
  

Baseline

1y of ETI

A

Platelets (N*103/mmc)

254 (245-273)

288 (230-347)a

248 (201-287)a,b

Leucocytes (N*103/mmc)

7.1 (6.6-7.7)

7.6 (6.3-9.6)a

6.5 (5.4-7.7)a,b

ALT (U/L)

22 (17-26)

22 (14-30)

27 (20-44)a,b

ALT/platelets

0.08 (0.06-0.10)

0.07 (0.04-0.13)

0.13 (0.07-0.22)a,b

CRP (mg/dL)

N.A.

0.37 (0.33-0.92)

0.33 (0.10-0.33)b

OAC (N/year)

N.A.

1.8 (2.0)

0.3 (0.6)b

IAC (N/year)

N.A.

0.5 (1.0)

0.01 (0.1)b

B

Platelets (N*103/mmc)

298 (261-322)

320 (261-400)a

283 (234-332)b

Leucocytes (N*103/mmc)

7.1 (6.7-7.7)

7.9 (6.8-10.1)a

6.8 (5.5-7.7)a,b

ALT (U/L)

21 (19-24)

22 (18-34)

23 (17-31)

ALT/platelets

0.07 (0.06-0.08)

0.07 (0.05-0.11)

0.08 (0.05-0.14)a,b

CRP (mg/dL)

N.A.

0.29 (0.06-0.47)

0.20 (0.06-0.33)b

OAC (N/year)

N.A.

1.7 (1.6)

0.7 (1.0)b

IAC (N/year)

N.A.

0.6 (1.6)

0.1 (0.3)b

  1. Data are reported as median (interquartile range) or average (standard deviation) as appropriate. a p < 0.01 vs CTRL, Mann-Whitney U test; b p < 0.01 vs baseline, Wilcoxon test. HCs: healthy control subjects; pwCF: people with CF; ETI: elexacaftor/tezacaftor/ivacaftor; ALT: alanine aminotransferase; CRP: C reactive protein; N.A : not available; OAC: oral antibiotic cycles; IAC: intravenous antibiotic cycles.
Back to article page